Pfizer Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pfizer (New York, NY): 214 reconciled FDA prescription therapies (16.0% 2025 to 2030 cliff risk), $12.57B 2024 CMS Part D & Medicaid spend, and 555 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNew York, NY
Reconciled FDA Portfolio Therapies214
2025 to 2030 Patent-Cliff Revenue Exposure16.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$12.57B
2024 Medicare Part D Spend$9.43B
2024 Medicaid Spend$3.14B
California HCAI SB 17 Filings555 WAC filings (max 806.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.